J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...

Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data ...

Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a ...

Japan’s biopharmaceutical logistics market is propelled by demand for temperature-sensitive advanced therapies, regulatory ...

Keeping that in mind, LogiPharma Europe wanted to find ways to remedy that challenge, and welcomed a panel discussion on “Future-Proofing for Complex Novel Modalities: How Can You Deliver Personalized ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

The theory behind antibody drug conjugates (ADCs ... 2022, 40, 1255-1263. Norsworthy, K. J., et al. FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33 ...

The guidelines for treating seasonal allergic rhinitis with medications suggest that you use intranasal corticosteroids ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Tom Nolan reviews this week’s research It wasn’t long ago that we’d routinely. advise people with heart failure and fluid overload to restrict their fluid intake. Nowadays, restriction advice is ...

Belgian biotech Argenx has lost its development partner for acute myeloid leukaemia antibody cusatuzumab, after Johnson & Johnson backed away from the alliance after two and a half years.

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...